Skip to main content
MANE
NYSE Life Sciences

Veradermics Director Enright Sells $75.2M in Stock at $150.38

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$129.66
Mkt Cap
$5.471B
52W Low
$32
52W High
$156.63
52W Position info
305% above low
Off High info
17% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

MANE has more than doubled off its 52-week low of $32.

Summary

Director Patrick Enright's Longitude Capital funds sold 500,000 Veradermics shares for $75.19 million at $150.38, extending a 90-day stretch of heavy insider distribution.


Key Events · Ownership and Investor Activity · MANE

  • Director-Linked Funds Sell $75.2M

    On 2026-11-11, Longitude Venture Partners V and Longitude 103.8 East sold 500,000 shares at $150.38 for $75,190,000.

  • Sale Priced Above Current Market

    At $150.38, the transaction price sits about 16% above today's $129.66 quote, meaning the shares cleared at a higher level than the current market.

  • Adds to 90-Day Distribution

    The sale brings 90-day open-market insider selling to $92.4 million, with zero purchases across six active insiders.

  • Holdings After Sale

    Post-transaction indirect holdings stand at 2,350,399 and 1,803,474 shares across the two Longitude entities.


Analysis · MANE · Life Sciences

A director-affiliated venture fund sold 500,000 shares for $75.19 million at $150.38 per share — roughly 1.4% of the company's market value and about 16% above today's $129.66 price. That makes it the largest single insider sale in a 90-day window already showing $92.4 million of net distribution across six insiders. The timing lands days after positive 12-month Phase 2/3 data and a Q3 report showing $798.4 million in cash. Because the seller is a financial sponsor (Longitude Capital) rather than an operating executive, the move reads more as portfolio liquidity than a verdict on the business — but the cumulative selling overhang is real.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MANE was trading at $129.66 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $32.00 to $156.63. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MANE - Latest Insights

MANE
Nov 10, 2026, 4:57 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $148.44
Real-time Price: $129.66 info
Change: -$18.78 (-13%) info
Market Cap: $5.471B info
MANE
Nov 10, 2026, 8:54 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $142.72
Real-time Price: $129.66 info
Change: -$13.06 (-9%) info
Market Cap: $5.471B info
MANE
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $142.00
Real-time Price: $129.66 info
Change: -$12.34 (-9%) info
Market Cap: $5.471B info
MANE
Nov 08, 2026, 6:00 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $139.33
Real-time Price: $129.66 info
Change: -$9.67 (-7%) info
Market Cap: $5.471B info
MANE
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $108.01
Real-time Price: $129.66 info
Change: +$21.65 (+20%) info
Market Cap: $5.471B info